ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Big pharma partners sign Parkinson’s pact

by Michael McCoy
September 4, 2017 | APPEARED IN VOLUME 95, ISSUE 35

AstraZeneca and Takeda Pharmaceutical are joining to develop MEDI1341, an antibody from AstraZeneca intended to treat Parkinson’s disease. MEDI1341 binds to and inhibits α-synuclein, a protein that accumulates in the nerve cells of people with Parkinson’s. Takeda will pay AstraZeneca up to $400 million. AstraZeneca will lead Phase I clinical trials, which are set to start later this year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment